JPWO2020238763A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020238763A5 JPWO2020238763A5 JP2021569341A JP2021569341A JPWO2020238763A5 JP WO2020238763 A5 JPWO2020238763 A5 JP WO2020238763A5 JP 2021569341 A JP2021569341 A JP 2021569341A JP 2021569341 A JP2021569341 A JP 2021569341A JP WO2020238763 A5 JPWO2020238763 A5 JP WO2020238763A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- nucleotide
- nucleotides
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910440575 | 2019-05-24 | ||
| CN201910440575.8 | 2019-05-24 | ||
| PCT/CN2020/091624 WO2020238763A1 (zh) | 2019-05-24 | 2020-05-21 | 核酸、药物组合物与缀合物及制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535708A JP2022535708A (ja) | 2022-08-10 |
| JPWO2020238763A5 true JPWO2020238763A5 (zh) | 2023-05-29 |
Family
ID=73553779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569341A Pending JP2022535708A (ja) | 2019-05-24 | 2020-05-21 | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220186221A1 (zh) |
| EP (1) | EP3978029A4 (zh) |
| JP (1) | JP2022535708A (zh) |
| KR (1) | KR20220012284A (zh) |
| CN (2) | CN113795280B (zh) |
| AU (1) | AU2020282453A1 (zh) |
| CA (1) | CA3140233A1 (zh) |
| WO (1) | WO2020238763A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| EP3719128A4 (en) | 2017-12-01 | 2021-10-27 | Suzhou Ribo Life Science Co., Ltd. | DOUBLE STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE WITH DOUBLE STRANDED OLIGONUCLEOTIDE, METHOD OF MANUFACTURING THEREOF AND USE THEREOF |
| EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID AND METHOD OF USE THEREOF |
| WO2020063198A1 (zh) | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
| DK2640700T3 (en) | 2010-11-15 | 2019-01-14 | Life Technologies Corp | AMINOUS TRANSFECTION REAGENTS AND METHODS FOR PREPARING USE THEREOF |
| JP2015525797A (ja) | 2012-08-06 | 2015-09-07 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 糖質コンジュゲートｒｎａ剤およびその調製方法 |
| CN114015692A (zh) * | 2013-03-14 | 2022-02-08 | 阿尔尼拉姆医药品有限公司 | 补体组分C5 iRNA组合物及其使用方法 |
| PT2992098T (pt) | 2013-05-01 | 2019-07-05 | Ionis Pharmaceuticals Inc | Composições e métodos para modular a expressão de hbv e ttr |
| DK3019200T3 (da) | 2013-07-11 | 2022-06-20 | Alnylam Pharmaceuticals Inc | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf |
| AU2015269053A1 (en) * | 2014-06-06 | 2016-12-22 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| KR102494171B1 (ko) * | 2014-08-20 | 2023-02-02 | 알닐람 파마슈티칼스 인코포레이티드 | 변형 이중-가닥 rna 제제 |
| US10036017B2 (en) * | 2015-02-17 | 2018-07-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA |
| WO2016201301A1 (en) * | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| US20220395526A1 (en) * | 2017-12-01 | 2022-12-15 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, and preparation method and use |
| CN110944675B (zh) * | 2017-12-01 | 2024-06-04 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
-
2020
- 2020-05-21 KR KR1020217041240A patent/KR20220012284A/ko unknown
- 2020-05-21 CN CN202080033909.0A patent/CN113795280B/zh active Active
- 2020-05-21 EP EP20814338.8A patent/EP3978029A4/en active Pending
- 2020-05-21 JP JP2021569341A patent/JP2022535708A/ja active Pending
- 2020-05-21 AU AU2020282453A patent/AU2020282453A1/en active Pending
- 2020-05-21 US US17/595,577 patent/US20220186221A1/en active Pending
- 2020-05-21 CN CN202410300945.9A patent/CN118217305A/zh active Pending
- 2020-05-21 CA CA3140233A patent/CA3140233A1/en active Pending
- 2020-05-21 WO PCT/CN2020/091624 patent/WO2020238763A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503929A5 (zh) | ||
| JP2021503940A5 (zh) | ||
| JP2021503930A5 (zh) | ||
| US6670461B1 (en) | Oligonucleotide analogues | |
| JP2010538677A5 (zh) | ||
| JP2021502120A (ja) | 細胞におけるｌｐａの発現を抑制するための核酸 | |
| JP7376952B2 (ja) | ｓｉＲＮＡ複合体及びその調製方法と使用 | |
| JP2021500025A5 (zh) | ||
| JP2021503941A5 (zh) | ||
| JPH06502300A (ja) | 遺伝子発現の抑制のための化合物及び方法 | |
| JPWO2019105414A5 (zh) | ||
| JPWO2017010575A1 (ja) | β２ＧＰＩ遺伝子発現抑制核酸複合体 | |
| JP2022507282A (ja) | 細胞におけるｌｐａの発現を抑制するための核酸 | |
| WO2020072991A1 (en) | Modified oligomeric compounds and uses thereof | |
| JPWO2020233655A5 (zh) | ||
| EP2976351B1 (en) | Lipohillic oligonucleotide analogs | |
| JPWO2019156020A1 (ja) | 核酸分子の製造方法 | |
| WO2019022196A1 (ja) | 一本鎖オリゴヌクレオチド | |
| JPWO2020238763A5 (zh) | ||
| JPWO2019105435A5 (zh) | ||
| JPWO2020063198A5 (zh) | ||
| JPWO2020233650A5 (zh) | ||
| JPWO2019079781A5 (zh) | ||
| CN116769780A (zh) | 用于抑制补体因子B表达的siRNA、其缀合物和药物组合物及其用途 | |
| RU2021134268A (ru) | Нуклеиновая кислота, фармацевтическая композиция и конъюгат, способ получения и применение |